IL291958A - 1,2,4-oxadiazole derivatives as liver x receptor agonists - Google Patents

1,2,4-oxadiazole derivatives as liver x receptor agonists

Info

Publication number
IL291958A
IL291958A IL291958A IL29195822A IL291958A IL 291958 A IL291958 A IL 291958A IL 291958 A IL291958 A IL 291958A IL 29195822 A IL29195822 A IL 29195822A IL 291958 A IL291958 A IL 291958A
Authority
IL
Israel
Prior art keywords
methyl
trifluoromethyl
phenyl
oxadiazol
dione
Prior art date
Application number
IL291958A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL291958A publication Critical patent/IL291958A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL291958A 2019-11-25 2020-11-23 1,2,4-oxadiazole derivatives as liver x receptor agonists IL291958A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962940061P 2019-11-25 2019-11-25
US202063106293P 2020-10-27 2020-10-27
PCT/IB2020/061053 WO2021105857A1 (en) 2019-11-25 2020-11-23 1,2,4-oxadiazole derivatives as liver x receptor agonists

Publications (1)

Publication Number Publication Date
IL291958A true IL291958A (en) 2022-06-01

Family

ID=73654860

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291958A IL291958A (en) 2019-11-25 2020-11-23 1,2,4-oxadiazole derivatives as liver x receptor agonists

Country Status (22)

Country Link
US (2) US11427586B2 (cg-RX-API-DMAC7.html)
EP (1) EP4065228A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023503320A (cg-RX-API-DMAC7.html)
KR (1) KR20220106778A (cg-RX-API-DMAC7.html)
CN (1) CN114746149A (cg-RX-API-DMAC7.html)
AU (1) AU2020394597B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022009942A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157657A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001323A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022006645A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220227A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000107A (cg-RX-API-DMAC7.html)
EC (1) ECSP22040362A (cg-RX-API-DMAC7.html)
IL (1) IL291958A (cg-RX-API-DMAC7.html)
JO (1) JOP20220124A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006151A (cg-RX-API-DMAC7.html)
PE (1) PE20221785A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551248A1 (cg-RX-API-DMAC7.html)
PY (1) PY2077235A (cg-RX-API-DMAC7.html)
TW (1) TW202132289A (cg-RX-API-DMAC7.html)
UY (1) UY38964A (cg-RX-API-DMAC7.html)
WO (1) WO2021105857A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022243907A1 (en) * 2021-05-20 2022-11-24 Novartis Ag Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists
KR102882404B1 (ko) 2022-10-28 2025-11-06 (주)케이메디켐 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
EP2753608A1 (en) * 2011-09-08 2014-07-16 Allergan, Inc. 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1 phosphate receptors modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2015187840A2 (en) 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders
WO2020123869A1 (en) 2018-12-13 2020-06-18 eyeNOS, Inc. Lxr agonist in topical ophthalmic formulation for treatment of dry-eye disorder

Also Published As

Publication number Publication date
JP2023503320A (ja) 2023-01-27
US20220340573A1 (en) 2022-10-27
PH12022551248A1 (en) 2023-09-11
ECSP22040362A (es) 2022-06-30
MX2022006151A (es) 2022-08-02
EP4065228A1 (en) 2022-10-05
TW202132289A (zh) 2021-09-01
CN114746149A (zh) 2022-07-12
CA3157657A1 (en) 2021-06-03
CR20220227A (es) 2022-06-15
AU2020394597B2 (en) 2024-03-14
KR20220106778A (ko) 2022-07-29
BR112022009942A2 (pt) 2022-08-09
DOP2022000107A (es) 2022-06-15
UY38964A (es) 2021-06-30
CO2022006645A2 (es) 2022-05-31
JOP20220124A1 (ar) 2022-05-23
WO2021105857A1 (en) 2021-06-03
CL2022001323A1 (es) 2023-03-24
US20220064164A1 (en) 2022-03-03
AU2020394597A1 (en) 2022-06-02
PE20221785A1 (es) 2022-11-22
PY2077235A (es) 2022-10-31
US11427586B2 (en) 2022-08-30

Similar Documents

Publication Publication Date Title
AU2019291794B2 (en) Substituted naphthyridinone compounds useful as T cell activators
DK2497470T3 (en) Imidazotriaziner and imidazopyrimidines as kinase inhibitors
JP5129812B2 (ja) ビシクロアニリン誘導体
AU2024348443A1 (en) Novel phthalazine derivative compound as SOS1 inhibitors and use thereof
CN116648250A (zh) 作为sos1抑制剂的新型喹唑啉衍生物及其用途
RU2430923C2 (ru) Тиазолилдигидрохиназолины
ES2807785T3 (es) Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
CA3246797A1 (en) Nlrp3 inflammasome inhibitor and application thereof
AU2004272437A1 (en) CRF antagonists and heterobicyclic compounds
KR102345381B1 (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
KR20240147983A (ko) 펩티딜 니트릴 화합물과 그 용도
RU2012139182A (ru) ПИРИДО[3,2-d]ПИРИМИДИНЫ - ИНГИБИТОРЫ PI3К ДЕЛЬТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP7237017B2 (ja) オートファジーモジュレーターとして使用される化合物、ならびにその調製方法および使用
JP2017523223A5 (cg-RX-API-DMAC7.html)
ES2976515T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
TWI635082B (zh) 3-((雜-)芳基)-8-胺基-2-側氧-1,3-二氮雜-螺-[4.5]-癸烷衍生物
RU2013104038A (ru) СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ PI3K p110 ДЕЛЬТА ПУРИНОВЫЕ СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU2011258005A1 (en) Heterocyclic compounds as Janus kinase inhibitors
RU2019108717A (ru) Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
RU2014106999A (ru) Замещенные производные 3-тиазолоаминопропионовой кислоты и их применение в качестве фармацевтических препаратов
EP4110784A1 (en) Pyrimido[5,4-d]pyrimidine derivatives as ent inhibitors for the treatment of cancers, and combination thereof with adenosine receptor antagonists
AU2021396593A1 (en) Novel compounds as androgen receptor and phosphodiesterase dual inhibitor
AU2026202790A1 (en) Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JP2023503320A5 (cg-RX-API-DMAC7.html)
KR101896924B1 (ko) 신규한 항암제